Invesco Ltd. Has $28.50 Million Holdings in Jazz Pharmaceuticals PLC $JAZZ

Key Points

• Invesco Ltd. increased its stake in Jazz Pharmaceuticals PLC by 11.7% during the first quarter, owning approximately 0.37% of the company with a value of $28.5 million.
• Analyst ratings for Jazz Pharmaceuticals show a consensus of "Moderate Buy" with a price target adjusted downwards to $181.43 from earlier higher estimates.
• Jazz Pharmaceuticals reported a significant loss with an EPS of ($8.25) for the last quarter, missing estimates and indicating a negative net margin of 9.91%.

Invesco Ltd. grew its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 11.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 229,540 shares of the specialty pharmaceutical company's stock after acquiring an additional 24,060 shares during the period. Invesco Ltd. owned about 0.37% of Jazz Pharmaceuticals worth $28,497,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of JAZZ. Atlas Capital Advisors Inc. lifted its position in shares of Jazz Pharmaceuticals by 1,378.8% during the first quarter. Atlas Capital Advisors Inc. now owns 4,614 shares of the specialty pharmaceutical company's stock worth $573,000 after purchasing an additional 4,302 shares during the last quarter. Covestor Ltd increased its stake in shares of Jazz Pharmaceuticals by 12.8% in the first quarter. Covestor Ltd now owns 1,163 shares of the specialty pharmaceutical company's stock valued at $145,000 after purchasing an additional 132 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Jazz Pharmaceuticals by 4.7% in the first quarter. JPMorgan Chase & Co. now owns 1,662,042 shares of the specialty pharmaceutical company's stock valued at $206,343,000 after purchasing an additional 74,501 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Jazz Pharmaceuticals by 18.2% in the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 132,415 shares of the specialty pharmaceutical company's stock valued at $16,439,000 after purchasing an additional 20,360 shares during the period. Finally, Measured Wealth Private Client Group LLC acquired a new position in shares of Jazz Pharmaceuticals during the first quarter valued at approximately $410,000. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

JAZZ has been the topic of a number of research analyst reports. Robert W. Baird lowered their price objective on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. Needham & Company LLC reaffirmed a "buy" rating and issued a $202.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday. Deutsche Bank Aktiengesellschaft began coverage on shares of Jazz Pharmaceuticals in a research note on Tuesday, July 15th. They issued a "buy" rating and a $152.00 price objective for the company. Wall Street Zen lowered shares of Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 15th. Finally, Royal Bank Of Canada reduced their price objective on shares of Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. Thirteen investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, Jazz Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $181.43.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of the business's stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $107.63, for a total value of $107,630.00. Following the transaction, the chief executive officer directly owned 436,973 shares in the company, valued at $47,031,403.99. The trade was a 0.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.30% of the stock is currently owned by insiders.

Jazz Pharmaceuticals Price Performance

NASDAQ JAZZ traded up $2.58 on Friday, reaching $123.11. The company's stock had a trading volume of 726,062 shares, compared to its average volume of 833,761. The firm has a market cap of $7.47 billion, a PE ratio of -18.29, a price-to-earnings-growth ratio of 7.76 and a beta of 0.34. The business has a 50-day moving average price of $112.73 and a 200 day moving average price of $117.12. Jazz Pharmaceuticals PLC has a 52 week low of $95.49 and a 52 week high of $148.06. The company has a current ratio of 1.62, a quick ratio of 1.37 and a debt-to-equity ratio of 1.17.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share for the quarter, missing analysts' consensus estimates of ($5.61) by ($2.64). The business had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.05 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The business's revenue was up 2.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $5.30 EPS. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. Sell-side analysts expect that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.